Drugs / MNI-558
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01217021 | Sep 2010 → Mar 2011 | Alzheimer disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNI-558 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01217021 ↗ |
| Known as | [18F]MNI-558 | “a radioactive drug, [18F]MNI-558 that binds to beta-amyloid.” NCT01217021 ↗ |
| Route | Intravenous | “single IV injection” NCT01217021 ↗ |